Bicycle Therapeutics PLC
BCYC- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001761612
In the last 90 days, Bicycle Therapeutics PLC insiders filed 0 open-market purchases and 5 sales; 103 institutions reported holding it in 13F filings for Q2 2026, worth $157.9M in total; no superinvestor holds it.
13F holders, Q4 2021
Institutional positions in Bicycle Therapeutics PLC as of Dec 31, 2021. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 101
- +33 vs. Q3 2021
- Shares held
- 21.6M
- +7.37M (+51.9%) vs. Q3 2021
- Total value
- $1.31B
- +$721.6M (+122.2%) vs. Q3 2021
- New holders
- 45
- 26 more added
- Sold out
- 12
- 25 more reduced
1 institution that held it in Q3 2021 haven't filed for Q4 2021 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q3 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting BCYC on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 103 | $157.9M |
| Q1 2026 | 98 | $173.6M |
| Q4 2025 | 109 | $276.9M |
| Q3 2025 | 99 | $285.6M |
| Q2 2025 | 110 | $286.3M |
| Q1 2025 | 95 | $354.4M |
| Q4 2024 | 97 | $586.5M |
| Q3 2024 | 105 | $915.3M |
| Q2 2024 | 107 | $804.0M |
| Q1 2024 | 95 | $759.1M |
| Q4 2023 | 101 | $567.4M |
| Q3 2023 | 101 | $651.3M |
| Q2 2023 | 85 | $618.5M |
| Q1 2023 | 89 | $498.9M |
| Q4 2022 | 87 | $695.9M |
| Q3 2022 | 79 | $538.0M |
| Q2 2022 | 82 | $381.1M |
| Q1 2022 | 105 | $884.5M |
| Q4 2021 | 101 | $1.31B |
| Q3 2021 | 69 | $591.1M |
| Q2 2021 | 54 | $376.9M |
| Q1 2021 | 39 | $341.2M |
Institutions, Q4 2021
Shares, value and share of portfolio for each institution holding Bicycle Therapeutics PLC; share changes are against Q3 2021.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Ridgeback Capital Investments L.P. | 2,164,801 | $131.8M | 71.77% | +2,164,801 | New |
| Atlas Venture Advisors, Inc. | 0 | $0 | 0.00% | −307,696−100.0% | Sold out |
| Ghost Tree Capital, LLC | 0 | $0 | 0.00% | −100,000−100.0% | Sold out |
| Schonfeld Strategic Advisors LLC | 0 | $0 | 0.00% | −59,972−100.0% | Sold out |
| Moody Aldrich Partners LLC | 0 | $0 | 0.00% | −59,053−100.0% | Sold out |
| Acuta Capital Partners, LLC | 0 | $0 | 0.00% | −38,184−100.0% | Sold out |
| Susquehanna International Group, LLP | 0 | $0 | 0.00% | −18,475−100.0% | Sold out |
| Bank of New York Mellon Corp | 0 | $0 | 0.00% | −8,490−100.0% | Sold out |
| Glenmede Trust Co NA | 0 | $0 | 0.00% | −6,436−100.0% | Sold out |
| State of New Jersey Common Pension Fund D | 0 | $0 | 0.00% | −4,880−100.0% | Sold out |
| KBC Group NV | 0 | $0 | 0.00% | −3,750−100.0% | Sold out |
| Evolution Wealth Advisors, LLC | 0 | $0 | 0.00% | −120−100.0% | Sold out |
| Deutsche Bank AG | 0 | $0 | 0.00% | −1−100.0% | Sold out |
| Marshall Wace North America L.P. | – | – | – | – | Not filed |